Systemic Lupus Erythematosus Market Size is Estimated to grow at a CAGR of 6.0% during the forecast period
The global systemic lupus erythematosus market size
is expected to register growth at a CAGR of 6.0% over the forecast period of
2022-2030.
The complicated chronic autoimmune illness known as
systemic lupus erythematosus (SLE), or simply lupus, causes inflammation of the
body's tissues. The illness frequently manifests as weariness, fever, rashes on
the skin, joint discomfort, malaise, and momentary loss of cognitive function.
The indications and manifestations may differ amongst people.
The illness affects connective tissues, which provide
various organs and structures in the body their strength and flexibility. These
include the kidneys, skin, joints, lungs, central nervous system, and
hematopoietic (blood-forming) system. There is currently no clear primary
etiology for the illness, but a number of studies have identified a complicated
genetic and hormonal basis.
Request
For Free Sample Pages @ https://www.xresearch.biz/request-sample-pages/systemic-lupus-erythematosus-market
GROWTH DRIVERS:
The global market for systemic lupus erythematosus is
primarily being driven by factors such as the increasing prevalence of
autoimmune diseases worldwide, the growing awareness of lupus and SLE
treatments worldwide, the increasing arrival of key pipeline agents that
promise higher efficacy than the currently available therapies, the rapid
introduction of new biological therapies, and the increasing R&D investment
in SLE drugs.
Furthermore, because biologics for autoimmune diseases
significantly improve disease management, doctors are beginning to approve and
trust them more and more. Additionally, a number of important pipeline
biologics that are completing phase III clinical studies are projected to enter
the market in the next years and are predicted to drive demand since they may
provide more effective alternatives for the subset of patients with lupus
nephritis. Benlysta is becoming more and more in demand, particularly in the
developed areas. In the next years, each of these variables is anticipated to
have a major impact on the market's growth.
Additionally, the SLE Market is
expected to grow during the forecast period due to factors like the high level
of unmet needs in the market for therapies that can improve patients' quality
of life and reduce the need for corticosteroids, the growing number of
manufacturers making significant efforts to develop biologics with higher efficacy,
and the growing number of large players entering the market with promising
therapies.
SYSTEMIC LUPUS ERYTHEMATOSUS MARKET
SEGMENTATION:
By Drug Classes:
· NSAID
· Corticosteroids
· Antimalarials
· Immunosuppressants
· Biologics
By Route of Administration:
· Oral
· Intravenous
· Subcutaneous
· Topical
By Distribution Channel:
· Retail
Pharmacies
· Hospitals
· Online
Pharmacies
By Region:
· North
America
· Europe
· Asia
Pacific
· Latin
America
· Middle
East and Africa
KEY COMPANIES IN SYSTEMIC LUPUS ERYTHEMATOSUS
MARKET:
· Pfizer
· Novartis
· Bayer
· Amgen
Inc.
· Bristol-Myers
Squibb Company
· GlaxoSmithKline
PLC
· Immunomedics
Inc.
· Johnson
& Johnson
· MedImmune
LLC
· Merck
Serono GmbH
· Sanofi
SA
· Teva
Pharmaceutical Industries Ltd.
· UCB
SA
· F.
Hoffmann-La Roche Ltd.
· Hansa
Medical Ab
· Harbor
Biosciences
· Other
Players
For
More Information about this Report @ https://www.xresearch.biz/shop/systemic-lupus-erythematosus-market
About
Us: -
xResearch is a
market research and consulting organization that uses unique data, expert
analysis, and new technologies to create trusted intelligence on industries.
Our research is focused on delivering an informed and impartial view on
essential market data of industry, and it is primarily driven by an in-depth
study covering the following parameters: Market Sizing and Forecasting, Market
Segmentation, Competitive Analysis, Strategic Assessment and Business
Modelling.
Contact:
Company Name: xResearch
Contact Person: James Lin
Email: sales@xresearch.biz
Phone: +1 718-618-4545
Comments
Post a Comment